SSC
LUMO

Syverson Strege & Co’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History

Syverson Strege & Co’s Portfolio LUMO Stock Details LUMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-22
Closed -$73 – 653
2023
Q1 		$73 Hold
22
– – ﹤0.01% 662
2022
Q4 		$79 Hold
22
– – ﹤0.01% 312
2022
Q3 		$0 Hold
22
– – ﹤0.01% 342
2022
Q2 		$0 Hold
22
– – ﹤0.01% 351
2022
Q1 		$0 Hold
22
– – ﹤0.01% 336
2021
Q4 		$0 Hold
22
– – ﹤0.01% 492
2021
Q3 		$0 Hold
22
– – ﹤0.01% 477
2021
Q2 		$0 Hold
22
– – ﹤0.01% 297
2021
Q1 		$0 Hold
22
– – ﹤0.01% 287
2020
Q4 		$1K Buy
+22
New +$379 ﹤0.01% 242

Other funds holding LUMO

Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AI
Acuitas Investments Seattle, Washington $1.41M AUM 48.57% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return

Syverson Strege & Co's LUMO Position: Q2 2023 in Review

Syverson Strege & Co sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q2 2023, closing a stake of 22 shares — an estimated $73 sold.

Syverson Strege & Co first reported a position in LUMO in Q4 2020 and held it in 10 quarters. The position peaked at $1K in Q4 2020. 34 funds tracked by Wall St. Rank hold LUMO as of Q2 2023.

  • Syverson Strege & Co reported no remaining Lumos Pharma, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Syverson Strege & Co sold 22 Lumos Pharma, Inc. Common Stock shares in Q2 2023, an estimated $73.
  • Syverson Strege & Co first reported a position in Lumos Pharma, Inc. Common Stock in Q4 2020 and held it in 10 quarters.
  • Syverson Strege & Co's Lumos Pharma, Inc. Common Stock position peaked at $1K in Q4 2020.
  • 34 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q2 2023.

Based on Syverson Strege & Co's 13F filing for Q2 2023, filed 4 Aug 2023.